Hanchuan Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanchuan Tao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aoshuang Li
Affiliated Dongtai Hospital of Nantong University, Nantong 224200, P. R. China
1 shared publication Cheng Wang
Department of Neurology, Dongtai People’s Hospital, Yancheng, Jiangsu 224200, China
1 shared publication- Cheng Wang
Department of Neurology, Affiliated Dongtai Hospital of Nantong University, Yancheng, China
1 shared publication Chongmei Lu
Department of General Surgery, Dongtai People’s Hospital, Yancheng, Jiangsu 224200, China
1 shared publicationFang Wang
Department of General Surgery, Affiliated Dongtai Hospital of Nantong University, Yancheng, China
1 shared publication- Fei Song
Department of Hepatobiliary Surgery & Liver Transplantation, Liver Cancer Institute, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Zhongshan Hospital Fudan University, Shanghai, China
1 shared publication
Latest Publications
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2803-2814
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway
Background Hepatocellular carcinoma (HCC) is treated with sorafenib as a first-line treatment; however, resistance reduces its clinical effectiveness. It has been demonstrated that CCDC137 influences cell survival and proliferation. However, in HCC, its role in sorafenib resistance has not been thoroughly investigated. Objective This study examined how CCDC137 makes HCC cells resistant to sorafenib, with a focus on the Akt/mTOR signaling pathway. Methods HCC cell lines resistant to sorafenib (Huh7/sora) were generated by gradually increasing sorafenib concentrations in Huh7 cells. Bioinformatics analysis was performed on the Cancer Genome Atlas (TCGA)-hepatocellular carcinoma (LIHC) dataset and the GSE29721 dataset. The prognostic significance of CCDC137 was verified using Kaplan–Meier survival curves. Using the in vitro cell assays, the consequences of CCDC137 for the migration, apoptosis, invasion, and proliferation of parental HCC cells and sorafenib-resistant cells were assessed. The changes were analyzed using the Western blot test in the AKT/mTOR signaling pathway in resistant cells after CCDC137 knockdown or overexpression. Results CCDC137 was significantly elevated in Huh7/sora cells resistant to sorafenib and was linked to a poor outcome for individuals with HCC. CCDC137 knockdown reduced cell viability, induced apoptosis and inhibited migration and invasion in Huh7/sora cells. Conversely, CCDC137 overexpression in Huh7 cells enhanced sorafenib resistance. Mechanistically, CCDC137 activated the Akt/mTOR signaling pathway, AKT inhibition with MK2206 reversed opposition and increased apoptosis in resistant cells. Conclusion Through triggering the Akt/mTOR signaling pathway, CCDC137 encourages sorafenib resistance in HCC cells, potentially offering a treatment approach to combat sorafenib resistance in HCC cells.
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2803-2814
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway
Background Hepatocellular carcinoma (HCC) is treated with sorafenib as a first-line treatment; however, resistance reduces its clinical effectiveness. It has been demonstrated that CCDC137 influences cell survival and proliferation. However, in HCC, its role in sorafenib resistance has not been thoroughly investigated. Objective This study examined how CCDC137 makes HCC cells resistant to sorafenib, with a focus on the Akt/mTOR signaling pathway. Methods HCC cell lines resistant to sorafenib (Huh7/sora) were generated by gradually increasing sorafenib concentrations in Huh7 cells. Bioinformatics analysis was performed on the Cancer Genome Atlas (TCGA)-hepatocellular carcinoma (LIHC) dataset and the GSE29721 dataset. The prognostic significance of CCDC137 was verified using Kaplan–Meier survival curves. Using the in vitro cell assays, the consequences of CCDC137 for the migration, apoptosis, invasion, and proliferation of parental HCC cells and sorafenib-resistant cells were assessed. The changes were analyzed using the Western blot test in the AKT/mTOR signaling pathway in resistant cells after CCDC137 knockdown or overexpression. Results CCDC137 was significantly elevated in Huh7/sora cells resistant to sorafenib and was linked to a poor outcome for individuals with HCC. CCDC137 knockdown reduced cell viability, induced apoptosis and inhibited migration and invasion in Huh7/sora cells. Conversely, CCDC137 overexpression in Huh7 cells enhanced sorafenib resistance. Mechanistically, CCDC137 activated the Akt/mTOR signaling pathway, AKT inhibition with MK2206 reversed opposition and increased apoptosis in resistant cells. Conclusion Through triggering the Akt/mTOR signaling pathway, CCDC137 encourages sorafenib resistance in HCC cells, potentially offering a treatment approach to combat sorafenib resistance in HCC cells.
- 4 November 2025
- Published by World Scientific Pub Co Pte Ltd in Nano
Highly Pifithrin-μ Loaded Melanin Nanosphere: A Safe and Efficient Approach to Hepatocellular Carcinoma Therapy via Thermo-Controlled Drug Release
Pifithrin-[ ], a potent dual-pathway inhibitor of p53 and HSP70, suffers from poor aqueous solubility and dose-limiting systemic toxicity, which severely hinder its anticancer efficacy. To overcome these limitations, we developed melanin-based nanospheres (MNSs) through alkaline-driven self-polymerization of dopamine. Capitalizing on [ ]–[ ] stacking interactions, we achieved efficient surface loading of pifithrin-[ ] (forming MNS-[ ] with a high drug-loading capacity of 40%. The resulting MNS-[ ] platform exhibited excellent colloidal stability under simulated physiological conditions and displayed sustained, thermoresponsive drug release kinetics, retaining [ ] of the payload at physiological temperature while triggering rapid release at [ ]C. Flow cytometry and confocal microscopy analyzes confirmed enhanced cellular internalization of MNS-[ ] in HepG2 cells. Upon laser irradiation, MNS-[ ] mediated localized photothermal effects, enabling spatiotemporally controlled drug release and significant cytotoxicity, reducing HepG2 cell viability to 35% at 200[ ][ ]g/mL. In contrast, PEGylated MNS (MNS-PEG) controls showed negligible photothermal toxicity. In a HepG2 xenograft mouse model, the combination of MNS-[ ] and near-infrared (NIR) irradiation achieved superior tumor growth inhibition ([ ] reduction in tumor volume) compared to free pifithrin-[ ] monotherapy, attributable to enhanced tumor accumulation and on-demand drug release. Histopathological examination revealed extensive tumor necrosis in the combination group without observed systemic toxicity. This study highlights MNSs as a versatile and biocompatible nanoplatform for enhancing the therapeutic index of hydrophobic agents via photothermally augmented targeting and stimuli-responsive delivery.
- 4 November 2025
- Published by World Scientific Pub Co Pte Ltd in Nano
Highly Pifithrin-μ Loaded Melanin Nanosphere: A Safe and Efficient Approach to Hepatocellular Carcinoma Therapy via Thermo-Controlled Drug Release
Pifithrin-[ ], a potent dual-pathway inhibitor of p53 and HSP70, suffers from poor aqueous solubility and dose-limiting systemic toxicity, which severely hinder its anticancer efficacy. To overcome these limitations, we developed melanin-based nanospheres (MNSs) through alkaline-driven self-polymerization of dopamine. Capitalizing on [ ]–[ ] stacking interactions, we achieved efficient surface loading of pifithrin-[ ] (forming MNS-[ ] with a high drug-loading capacity of 40%. The resulting MNS-[ ] platform exhibited excellent colloidal stability under simulated physiological conditions and displayed sustained, thermoresponsive drug release kinetics, retaining [ ] of the payload at physiological temperature while triggering rapid release at [ ]C. Flow cytometry and confocal microscopy analyzes confirmed enhanced cellular internalization of MNS-[ ] in HepG2 cells. Upon laser irradiation, MNS-[ ] mediated localized photothermal effects, enabling spatiotemporally controlled drug release and significant cytotoxicity, reducing HepG2 cell viability to 35% at 200[ ][ ]g/mL. In contrast, PEGylated MNS (MNS-PEG) controls showed negligible photothermal toxicity. In a HepG2 xenograft mouse model, the combination of MNS-[ ] and near-infrared (NIR) irradiation achieved superior tumor growth inhibition ([ ] reduction in tumor volume) compared to free pifithrin-[ ] monotherapy, attributable to enhanced tumor accumulation and on-demand drug release. Histopathological examination revealed extensive tumor necrosis in the combination group without observed systemic toxicity. This study highlights MNSs as a versatile and biocompatible nanoplatform for enhancing the therapeutic index of hydrophobic agents via photothermally augmented targeting and stimuli-responsive delivery.
- Open Access
- 19 July 2022
- Published by Hindawi Limited in Genetics Research
- Vol. 2022, 1-14
Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma
Background. Liver hepatocellular carcinoma (LIHC) is the predominant type of liver cancer, and its treatment still faces great challenges presently. Mitochondrial inner membrane protein MPV17 is reported to be involved in multiple biological activities of cancers. Here, we seek to investigate the specific role and functions of MPV17 in LIHC progression. Methods. Firstly, MPV17 expressions in various tumors and corresponding normal samples and LIHC groups with various clinical features were analyzed, respectively. Next, the relationship between MPV17 expression and LIHC survival was analyzed and verified by AUC curves. Besides, differentially expressed genes (DEGs) for LIHC were screened from TCGA and then analyzed by GO and KEGG. Then, MPV17 was analyzed by prognostic model, Cox analysis, predictive nomogram, pathway correlation, and immunoassay. Finally, the functions of MPV17 were determined by CCK-8 and Tranwell assays. Results. In most tumors, MPV17 expression was higher than that in the normal group, and it was related to LIHC clinical features. In the LIHC survival analysis, highly expressed MPV17 was associated with a poor prognosis. Besides, 314 upregulated and 193 downregulated DEGs are mainly involved in the TNF signaling pathway and tyrosine metabolism. Through prognostic model, Cox analysis, and predictive nomogram, MPV17 had the prognostic value for LIHC. Gene-pathway correlation analysis showed that MPV17 had the strongest correlation with the G2M_checkpoint pathway. In an immunoassay, MPV17 had a strong correlation with many immune cells. Functional assays showed that MPV17 reduction in LIHC cells could inhibit cell invasion, migration, and proliferation. Conclusion. MPV17, as a tumor promoter, could be a new biomarker for LIHC diagnosis and prognosis and probably shed new light on the exploration of LIHC therapies.
- 19 July 2022
- Published by Hindawi Limited in Genetics Research
- Vol. 2022, 1-14
Open AccessComprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma
Background. Liver hepatocellular carcinoma (LIHC) is the predominant type of liver cancer, and its treatment still faces great challenges presently. Mitochondrial inner membrane protein MPV17 is reported to be involved in multiple biological activities of cancers. Here, we seek to investigate the specific role and functions of MPV17 in LIHC progression. Methods. Firstly, MPV17 expressions in various tumors and corresponding normal samples and LIHC groups with various clinical features were analyzed, respectively. Next, the relationship between MPV17 expression and LIHC survival was analyzed and verified by AUC curves. Besides, differentially expressed genes (DEGs) for LIHC were screened from TCGA and then analyzed by GO and KEGG. Then, MPV17 was analyzed by prognostic model, Cox analysis, predictive nomogram, pathway correlation, and immunoassay. Finally, the functions of MPV17 were determined by CCK-8 and Tranwell assays. Results. In most tumors, MPV17 expression was higher than that in the normal group, and it was related to LIHC clinical features. In the LIHC survival analysis, highly expressed MPV17 was associated with a poor prognosis. Besides, 314 upregulated and 193 downregulated DEGs are mainly involved in the TNF signaling pathway and tyrosine metabolism. Through prognostic model, Cox analysis, and predictive nomogram, MPV17 had the prognostic value for LIHC. Gene-pathway correlation analysis showed that MPV17 had the strongest correlation with the G2M_checkpoint pathway. In an immunoassay, MPV17 had a strong correlation with many immune cells. Functional assays showed that MPV17 reduction in LIHC cells could inhibit cell invasion, migration, and proliferation. Conclusion. MPV17, as a tumor promoter, could be a new biomarker for LIHC diagnosis and prognosis and probably shed new light on the exploration of LIHC therapies.